A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Summary

The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma. This research is being done because there is a need for better treatment options for advanced or recurring sarcoma. SB939 has been shown to shrink tumours in animals and some people and seems promising but it is not clear if it has any positive effects in sarcoma.

Timeline

Start

2010-10-21

Primary completion

2013-01-21

Completion

2014-01-16

Publications

• Results Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200dagger. Ann Oncol. 2015 May;26(5):973-981. doi: 10.1093/annonc/mdv033. Epub 2015 Jan 28.

Drugs

Indications